Cirrhosis Management Market By 2023 to 2033: Key Players and Market Share

BySanket Badgujar
Cirrhosis Management Market

The global cirrhosis management market, valued at USD 725 million in 2023, is set for remarkable expansion over the next decade. Recent market analysis forecasts a robust compound annual growth rate (CAGR) of 3.8%, with the market expected to achieve an impressive USD 1,052.3 million by 2033. This upward trend represents a significant acceleration from the 2.7% CAGR observed between 2018 and 2022.

This anticipated growth is primarily driven by the increasing global incidence of cirrhosis, largely attributed to rising hepatitis infections. Hepatitis, a leading cause of liver cirrhosis, continues to affect millions of individuals worldwide, highlighting the critical need for advanced and effective cirrhosis management solutions.

Get your Sample Report Cirrhosis Management Market

Additionally, the burgeoning geriatric population, which is more susceptible to chronic disorders including liver disease, is expected to positively influence market growth. As the global population ages, the demand for comprehensive cirrhosis management is projected to rise correspondingly.

Furthermore, modern lifestyle factors such as altered dietary habits and sedentary living are contributing to a higher incidence of liver-related health issues. These trends highlight the growing necessity for robust cirrhosis management options to address the increasing prevalence of liver conditions.

With these factors combined, the cirrhosis management market is on a promising path, poised to meet the growing health needs of populations worldwide. This dynamic market environment offers significant opportunities for healthcare providers, medical professionals, and pharmaceutical companies dedicated to combating liver disease.

Top Highlights from the FMI’s Analysis of the Cirrhosis Management Market:

  • North America gained a 39.2% market share in 2022. The colossal share of the region can be attributed to a large number of key players present there.
  • The United States cirrhosis management industry is expected to account for the majority of the share of the cirrhosis management industry.
  • The European market acquired a 26.7% share in the market in the historical period. Due to the prominent stake of the region in the market, businesses are expected to increase their capacity to serve the surging demand for cirrhosis management.
  • The technologically progressive nature of Germany is expected to boost its prominence in the market. FMI expects the country to account for more than 8.1% market share in 2023.
  • The Japanese cirrhosis management market is projected to record a market value of 2.9%, representing a relatively low market hold yet offering businesses new prospects for growth.
  • China and India are expected to record 4.3% and 4.1% CAGRs, respectively, over the forecast period.
  • Based on disease indication, alcoholic liver cirrhosis accounted for a market share of 72.3% in 2022.
  • Under the category of end users, hospitals are expected to register a market share of 44.7% in 2022.

Key Developments in the Market:

  • In January 2022, Alnylam and Novartis declared that they are collaborating to search for targeted therapy to bring back liver health. Both companies have confirmed to work jointly on the discovery and creation of siRNA-based targeted therapies aimed at regaining functional liver cells in patients suffering from complex liver disorders. The aim of this collaboration was to develop liver-targeted therapy as a substitute for transplantation for patients inflicted with liver disorders.
  • In September 2022, Versantis, a privately owned Swiss clinical-stage biotechnology firm, came into an agreement with GENFIT to obtain all its voting rights and share capital. This development fits the strategic vision of GENFIT to become a global leader in Acute-on-Chronic Liver Failure (ACLF).
  • By collaborating with Takeda Pharmaceuticals and Arrowhead Pharmaceuticals, School of Medicine scientists from Saint Louis University have developed the 1st effective medication to cure a rare genetic liver disorder earlier only treatable via liver transplantation. They successfully checked the safety and efficiency of fazirsiran, which is an RNA interference medication. 

Key Companies Profiled:

  • B. Braun Medical Inc.
  • Alliancells Bioscience Corporation Ltd.
  • Histogen Inc.
  • Stempeutics Research Pvt. Ltd.
  • Epic Research & Diagnostics Inc.
  • Theravance Biopharma R&D Inc.
  • Sequana Medical AG

Key Segments Profiled in the Cirrhosis Management Industry Survey:

By Treatment:

  • Treating Cirrhosis Causes
  • Antiviral Medications for Hepatitis B & C
  • Corticosteroids
  • Symptomatic Treatment
  • Analgesics
  • Treatment of Portal Hypertension (Beta-Blockers, Nitrates)
  • Treatment of Edema and Ascites (Diuretics, Antibiotics)
  • Avoid Complications
  • Banding Procedures/Band Ligation of Varics
  • Dialysis
  • Treatment of Osteoporosis
  • Vaccination for Flu and Other Complications
  • Liver Transplantation

By Disease Indication:

  • Alcoholic Liver
  • Non-Alcoholic Liver

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Research Institutes
  • Dialysis Centers
  • Clinics
  • Other Settings

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa